United States v. Kalantari

Court of Appeals for the Ninth Circuit·Decided March 10, 2026·No. 24-7125·Unpublished

Opinion

NOT FOR PUBLICATION FILED MAR 10 2026

UNITED STATES COURT OF APPEALS MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS

FOR THE NINTH CIRCUIT

UNITED STATES OF AMERICA, No. 24-4365 D.C. No.

Plaintiff - Appellee, 2:18-cr-00375-AB-4 v.

MEMORANDUM*

SHAHRIAR KALANTARI, AKA Michael Kalantari,

Defendant - Appellant.

UNITED STATES OF AMERICA, No. 24-7125 Plaintiff - Appellee, D.C. No.

2:18-cr-00375-AB-4

v.

SHAHRIAR KALANTARI, AKA Michael Kalantari,

Defendant - Appellant.

Appeal from the United States District Court for the Central District of California André Birotte, Jr., District Judge, Presiding

Argued and Submitted December 9, 2025

*

This disposition is not appropriate for publication and is not precedent except as provided by Ninth Circuit Rule 36-3.

Pasadena, California

Before: M. SMITH, CHRISTEN, and FORREST, Circuit Judges.

Defendant-Appellant Michael Kalantari was convicted by jury of one count of conspiracy to commit health care fraud in violation of 18 U.S.C. § 1349, three counts of health care fraud in violation of 18 U.S.C. § 1347, and one count of conspiracy to engage in the unlicensed wholesale distribution of prescription drugs in violation of 18 U.S.C. § 371 and 21 U.S.C. §§ 331(t), 333(b)(1)(D), and 353(e)(1)(A). On appeal, Kalantari challenges his convictions, the district court’s denial of his motion for a new trial based on newly discovered evidence, the district court’s denial of an evidentiary hearing after Kalantari moved for a new trial, and his sentence. Because the parties are familiar with the facts of this case, we do not recount them here except as necessary to provide context for our ruling. We have jurisdiction pursuant to 28 U.S.C. § 1291 and 18 U.S.C. § 3742(a). We affirm in part, reverse in part, and remand.

1. Reviewing for plain error, see Fed. R. Crim. P. 52(b), we first hold that the government did not plainly err by failing to correct false testimony from its key witness, Yigal Keren, in violation of Kalantari’s due process rights pursuant to Napue v. Illinois, 360 U.S. 264, 272 (1959). To establish a Napue violation, a defendant must demonstrate that: (i) the testimony was false; (ii) the government knew or should have known that the testimony was false; and (iii) the testimony

was material, “meaning there is a ‘reasonable likelihood that the false testimony could have affected the judgment of the jury.’” United States v. Renzi, 769 F.3d 731, 751 (9th Cir. 2014) (quoting United States v. Houston, 648 F.3d 806, 814 (9th Cir. 2011)).

We start with Keren’s testimony regarding his characterization of “patients”

versus “guests” at SOUL Housing, which we do not find “so clearly or obviously false such that [Kalantari] has demonstrated plain error.” United States v. Holmes, 163 F.4th 547, 574 (9th Cir. 2025). Regarding Keren’s testimony’s about whether he told Gary that he had “active” and “standby” patients, we conclude that, even if Keren’s testimony on this topic was false, Kalantari has failed to demonstrate that it was plainly material. See Houston, 648 F.3d at 814–15. Keren acknowledged on cross-examination that he “told people that [he] had 500 patients.”

We likewise conclude that Kalantari has not established a plain Napue violation with Keren’s denial that Kalantari asked to review patient files to see if they were real, Keren’s testimony about whether the patient files came from a “marketer,” and Keren’s testimony about whether he understood “the concept of the medical concierge.” Kalantari’s counsel impeached Keren with his prior inconsistent statements on these topics. Thus, Kalantari has not established a reasonable likelihood that the testimony “could have affected the judgment of the jury.” Holmes, 163 F.4th at 573 (internal quotations omitted).

Last, we conclude that Kalantari has not established a plain Napue violation with Keren’s testimony that Kalantari would receive 33% of the black-market sales price. We are not persuaded that Kalantari’s testimony about the payment scheme was plainly false, but even if it were false, Kalantari has not demonstrated that it was plainly material. Keren stated at other points during his testimony that Kalantari was paid $200 per prescription, and Kalantari’s counsel highlighted this testimony by impeaching Keren based on his prior testimony to FBI agents that Kalantari would be paid “$250 a prescription.”

2. “We review de novo whether a jury instruction misstates the law,” but “review the language and formulation of a jury instruction for abuse of discretion.” United States v. Rodriguez, 971 F.3d 1005, 1012 (9th Cir. 2020) (internal quotation omitted). We are not persuaded that the district court’s limiting instruction pursuant to Federal Rule of Evidence 404(b) was an erroneous statement of the law nor that the district court abused its discretion in giving it. The instruction tracks, albeit not exactly, the language in Ninth Circuit Pattern Jury Instruction 2.10 (2022 ed.). According to Kalantari, the pattern instruction requires the district court to make choices to tailor the instruction to the evidence in each case. However, he does not persuasively explain why the district court’s decision not to tailor the limiting instruction here rendered the instruction “misleading or inadequate to guide the jury’s deliberations.” United States v. Marsh, 26 F.3d 1496, 1502 (9th

Cir. 1994) (internal quotations omitted).

Kalantari also argues that the limiting instruction was an abuse of discretion because it improperly characterized his statements in the relevant recordings as “acts,” and it did so without evidence for the jury to conclude that Kalantari engaged in such acts beyond a reasonable doubt. Again, this argument is unpersuasive. The limiting instruction describes the relevant “evidence” as Kalantari’s “statements.” It does not, as Kalantari suggests, improperly invite the jury to conclude that Kalantari actually committed the acts contemplated in his statements without evidence. Regardless, even if it did, the error was harmless. See United States v. Hamilton, 171 F. Appx. 556, 558 (9th Cir. 2006) (mem.) (citing United States v. Washington, 106 F.3d 1488, 1490 (9th Cir. 1997) (per curiam)). Keren testified that they did not follow through with Kalantari’s proposals, and Kalantari’s counsel argued during closing that “nothing happened” and the statements in the recordings were “not true.”

3. Reviewing for abuse of discretion, see United States v. Mack, 362 F.3d 597, 600 (9th Cir. 2004), we affirm the district court’s decision to deny a new trial after the parties discovered a mistake with the Medi-Cal claims data that the government presented at trial. Newly discovered evidence warrants a new trial if the defendant can establish: “(1) the evidence is newly discovered; (2) the defendant was diligent in seeking the evidence; (3) the evidence is material to the

issues at trial; (4) the evidence is not (a) cumulative or (b) merely impeaching; and (5) the evidence indicates the defendant would probably be acquitted in a new trial.” United States v. Hinkson, 585 F.3d 1247, 1264 (9th Cir. 2009) (en banc).

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Kalantari, (9th Cir. 2026).

United States v. Kalantari (United States v. Kalantari) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Atkinson
297 U.S. 157 (Supreme Court, 1936)
Napue v. Illinois
360 U.S. 264 (Supreme Court, 1959)
Brady v. Maryland
373 U.S. 83 (Supreme Court, 1963)
Jones v. United States
527 U.S. 373 (Supreme Court, 1999)
United States v. Houston
648 F.3d 806 (Ninth Circuit, 2011)
United States v. David Peter Marsh
26 F.3d 1496 (Ninth Circuit, 1994)
United States v. Leroy Roosevelt Mack
362 F.3d 597 (Ninth Circuit, 2004)
United States v. Hinkson
585 F.3d 1247 (Ninth Circuit, 2009)
United States v. Richard Renzi
769 F.3d 731 (Ninth Circuit, 2014)
United States v. Eve Mazzarella
784 F.3d 532 (Ninth Circuit, 2015)
United States v. Gary Conti
804 F.3d 977 (Ninth Circuit, 2015)
Ocasio v. United States
578 U.S. 282 (Supreme Court, 2016)
United States v. James Murphy
824 F.3d 1197 (Ninth Circuit, 2016)
United States v. Rosario Vazquez-Hernandez
849 F.3d 1219 (Ninth Circuit, 2017)
United States v. Alejandro Aguilar Diaz
884 F.3d 911 (Ninth Circuit, 2018)